[144] BIO-RAD LABORATORIES, INC. SEC Filing

Rhea-AI Filing Summary

BIO: A holder filed a Form 144 notice to sell up to 701 common shares on the NYSE. The filing lists Morgan Stanley Smith Barney LLC as broker and shows an aggregate market value $214,633.08 for the proposed sale, with an approximate sale date 11/06/2025.

The shares were acquired through restricted stock and an employee stock purchase plan in multiple lots: 214 (restricted on 09/06/2025), 385 (restricted on 09/01/2025), 70 (restricted on 09/03/2024), 29 (ESPP on 03/28/2024), and 3 (ESPP on 12/29/2023), totaling 701. Shares outstanding were 21,906,399; this is a baseline figure, not the amount being offered.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	701	214633.08	21906399	11/06/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/06/2025	Restricted Stock	Issuer			214	09/06/2025	Not Applicable
Common	09/01/2025	Restricted Stock	Issuer			385	09/01/2025	Not Applicable
Common	09/03/2024	Restricted Stock	Issuer			70	09/03/2024	Not Applicable
Common	03/28/2024	Employee Stock Purchase Plan	Issuer			29	03/28/2024	Cash
Common	12/29/2023	Employee Stock Purchase Plan	Issuer			3	12/29/2023	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does BIO’s Form 144 filing disclose?

A proposed sale of up to 701 common shares with an aggregate market value of $214,633.08 on the NYSE.

Who is the broker for the proposed BIO share sale?

The filing lists Morgan Stanley Smith Barney LLC as broker.

When is the approximate sale date in the BIO Form 144?

The approximate sale date is 11/06/2025.

How many BIO shares are outstanding according to the notice?

The filing shows 21,906,399 shares outstanding.

How were the BIO shares to be sold acquired?

Through restricted stock (214, 385, 70 shares) and the employee stock purchase plan (29 and 3 shares).

How many BIO shares are proposed for sale and what is the value?

Up to 701 shares with an aggregate market value of $214,633.08.

On which exchange are the BIO shares listed for this sale?

The filing names the NYSE as the exchange.